Advanced Search

 

Study ID Status Title Patient Level Data
49653/109 Completed An Open-label, Positive-controlled, Parallel-group Study to Determine the Effect of BRL 49653C, Rosiglitazone, on Body Fat Distribution When Administered for 26 Weeks to Patients with Type 2 Diabetes Study Listed on ClinicalStudyDataRequest.com
49653/112 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Study Listed on ClinicalStudyDataRequest.com
49653/113 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of 49653 When Administered Once or Twice Daily in Combination with Metformin to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/114 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Insulin to Patients with Type 2 Diabetes Study Listed on ClinicalStudyDataRequest.com
49653/116 Completed An Investigation of the Effect of Rosiglitazone Maleate (BRL 49653C) Versus Troglitazone on the Safety, Tolerability and Pharmacokinetics of Triazolam in Healthy Volunteers
49653/117 Completed A Study to Evaluate the Relative Bioavailability of Two Enterically-Coated Formulations of Rosiglitazone Compared to the Immediate Release Formulation of Rosiglitazone in Healthy Volunteers.
49653/121 Completed An Investigation of the Pharmacokinetics of Single 4 mg and Repeat 4 mg Twice Daily and Single and Repeat 8 mg Once Daily Doses of Rosiglitazone in Healthy Volunteers
49653/125 Completed An Open-Label Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Type 2 Diabetes
49653/127 Completed A 26-Week Randomized, Double-Blind Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone 8mg/day (4mg bd) Versus Placebo in Combination with Glyburide in Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Maximum Dose Glyburide
49653/128 Completed A double-blind, multicenter, placebo controlled, parallel group comparative study to evaluate the efficacy and safety of BRL 49653C (Avandia) with concurrent sulphonylurea therapy, when administered to patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/129 Completed An Evaluation of the Safety and Tolerability of Single Rising Doses of Rosiglitazone in Healthy Chinese male Subjects.
49653/130 Completed An Evaluation of the Safety, Tolerability and Pharmacokinetics of Rosiglitazone after 8 Days Repeat –Dosing to Healthy Chinese Subjects.
49653/131 Completed A Double-blind, Placebo-controlled, Parallel-group Study to Determine the Effect of BRL- 49653C Rosiglitazone, on Fat Distribution When Administered for 26 Weeks to Subjects With Impaired Glucose Tolerance (IGT) Study Listed on ClinicalStudyDataRequest.com
49653/132 Completed A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Non-Insulin-Dependent Diabetes Mellitus (Type 2 Diabetes)
49653/133 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone (BRL 49653C) When Administered Twice Daily in Combination with Glyburide to Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Maximum Dose Glyburide (from study 49653-127)
49653/134 Completed A 26-Week Randomized, Double-Blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone (2 mg BID and 4 mg BID) Versus Placebo in Combination with Glyburide and Metformin in Patients with Type 2 Diabetes Mellitus
49653/135 Completed 2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy Study Listed on ClinicalStudyDataRequest.com
49653/136 Completed A 26-week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Insulin Therapy and/or a Sulphonylurea in Type 2 Diabetic Patients with Chronic Renal Failure (Not on Dialysis). Study Listed on ClinicalStudyDataRequest.com
49653/140 Completed A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients. Study Listed on ClinicalStudyDataRequest.com
49653/142 Completed An evaluation of the Pharmacokinetics of Single Dose of Rosiglitazone in Healthy Chinese Male Subjects.
49653/143 Completed A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg once daily) in Combination with Glyburide in African American and Hispanic Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glyburide Monotherapy Study Listed on ClinicalStudyDataRequest.com
49653/147 Completed A multicentre, double-blind, placebo-controlled, parallel group, comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone with concomitant oral therapy with sulphonylurea when administered for 26 weeks to patients withtype 2 diabetes and who are…
49653/151 Completed Clinical Evaluation of BRL49653C (BID) in Type-2 Diabetes Mellitus (Monotherapy) – Double-blind, dose response study.
49653/152 Completed A multicentre, open-label study (26 weeks) to evaluate the efficacy and tolerability of rosiglitazone when administered to patients with type 2 diabetes who are inadequately controlled with diet either alone or together with oral antidiabetic therapy
49653/154 Completed A multicentre, open label, comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone + metformin vs glibencamide + metformin (fixed combination) in type 2 diabetic subjects fairly controlled on up to half maximal dose of monotherapy drugs and requiring tighter metaboli ...

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.